Abstract
An interdisciplinary panel of specialists met in Mallorca in the first European Symposium on Morbid Obesity entitled; “Morbid Obesity, an Interdisciplinary Approach”. During the two and half days of the meeting, the participants discussed several aspects related to pathogenesis, evaluation, and treatment of morbid obesity. The expert panel included basic research scientists, dietitians and nutritionists, exercise physiologists, endocrinologists, psychiatrists, cardiologists, pneumonologists, anesthesiologists, and bariatric surgeons with expertise in the different weight loss surgeries. The symposium was sponsored by the Balearic Islands Health Department; however, this statement is an independent report of the panel and is not a policy statement of any of the sponsors or endorsers of the Symposium. The prevalence of morbid obesity, the most severe state of the disease, has become epidemic. The current recommendations for the therapy of the morbidly obese comes as a result of a National Institutes of Health (NIH) Consensus Conference held in 1991 and subsequently reviewed in 2004 by the American Society for Bariatric Surgery. This document reviews the work-up evaluation of the morbidly obese patient, the current status of the indications for bariatric surgery and which type of procedure should be recommended; it also brings up for discussion some important real-life clinical practice issues, which should be taken into consideration when evaluating and treating morbidly obese patients. Finally, it also goes through current scientific evidence supporting the potential effectiveness of medical therapy as treatment of patients with morbid obesity. Key-words: Morbid obesity, bariatric surgery, gastric bypass surgery, biliopancretic diversion, ghrelin, medical therapy.
Similar content being viewed by others
References
Flegal KM CM, Carroll MD, Ogden DL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288: 1723–7.
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999, 341: 1097–105.
Field A, Coakley EH, Must A, et al. Impact of overweight on the risk of develo** common chronic diseases during a 10-year period. Arch Intern Med 2001, 161: 1581–6.
Wang Y. Cross-national comparison of childhood obesity: the epidemic and the relationship between obesity and socioeconomic status. Int J Epidemiol 2001, 30: 1129–36.
Jung RT. Obesity as a disease. Br Med Bull 1997, 53: 307–21.
Buchwald H; Consensus Conference Panel. Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. J Am Coll Surg 2005, 200: 593–604.
Lobstein T, Frelut ML. Prevalence of overweight among children in Europe. Obes Rev 2003, 4: 195–200.
Department of Health 2001. Health Survey for England. www.doh.gov.uk/.
Aranceta-Bartrina J, Serra-Majem L, Foz-Sala M, Moreno-Esteban B; Grupo Colaborativo SEEDO. Prevalence of obesity in Spain. Med Clin (Barc) 2005, 125: 460–6.
Kaminsky J, Gadaleta D. A study of discrimination within the medical community as viewed by obese patients. Obes Surg 2002, 12: 14–8.
Cawley J, Danziger S. Morbid obesity and the transition from welfare to work. J Policy Anal Manage 2005, 24: 727–43.
NIH Conference: Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991, 115: 956–61.
Guidance on the use of surgery to aid weight reduction for people with morbid obesity. NICE Technology Appraisal Guidance — No. 46. 2002.
Sjostrom L, Lindroos AK, Peltonen M, et al; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351: 2683–93.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999, 282: 1523–9.
Cook CM, Edwards C. Success habits of long-term gastric bypass patients. Obes Surg 1999, 9: 80–2.
Sarwer DB, Cohn NI, Gibbons LM, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg 2004, 14: 1148–56.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346: 1623–30.
Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003, 11: 919–24.
Frühbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004, 350: 308–9.
Couce ME, Cottam DR, Esplen J, Schauer P, Burguera B. Is ghrelin the culprit of weight loss after gastric bypass surgery? A negative answer. Obes Surg 2006, 16: 870–8.
Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003, 88: 1594–602.
Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003, 88: 3177–83.
Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004, 12: 346–50.
Morínigo R, Moizé V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006, 91: 1735–40.
Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006, 243: 108–14.
Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000, 84: 441–61.
Wing RR, Blair EH, Marcus MD, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type 2 diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994, 97: 354–62.
Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004, 164: 994–1003.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27: 155–61.
Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001, 25: 1713–21.
Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004, 58: 582–7.
Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisnieewski, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001, 161: 218–27.
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353: 2111–20.
Frühbeck G, Rotellar F, Hernández-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg 2004, 14: 1208–15.
Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999, 7: 477–84.
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995, 222: 339–50.
Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V. Bilio-pancreatic bypass for obesity. II. Initial experience in man. Br J Surg 1979, 66: 619–20.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003, 238: 467–84.
Scopinaro N, Marinari GM, Camerini GB, Papadia FS, Adami GF. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005, 28: 2406–11.
Higa KD, Ho T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. J Laparoendosc Adv Surg Tech A. 2001, 11: 377–82.
Author information
Authors and Affiliations
Corresponding author
Additional information
The Authors’ affiliations are reported in the Appendix.
Rights and permissions
About this article
Cite this article
Burguera, B., Agusti, A., Arner, P. et al. Critical assessment of the current guidelines for the management and treatment of morbidly obese patients. J Endocrinol Invest 30, 844–852 (2007). https://doi.org/10.1007/BF03349226
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349226